This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gilbert, C.
Right arrow Articles by Boivin, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gilbert, C.
Right arrow Articles by Boivin, G.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, December 2001, p. 3669-3671, Vol. 45, No. 12
0066-4804/01/$04.00+0   DOI: 10.1128/AAC.45.12.3669-3671.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.

Lack of Emergence of Cytomegalovirus UL97 Mutations Conferring Ganciclovir (GCV) Resistance following Preemptive GCV Therapy in Allogeneic Stem Cell Transplant Recipients

C. Gilbert,1 J. Roy,2 R. Belanger,2 R. Delage,3 C. Beliveau,4 C. Demers,3 and G. Boivin1,*

Research Center in Infectious Diseases of the Centre Hospitalier Universitaire de Québec and Department of Medical Biology1 and Bone Marrow Transplant Unit, St.-Sacrement Hospital and Department of Medicine,3 Université Laval, and Department of Microbiology4 and Bone Marrow Transplant Unit, Maisonneuve-Rosemont Hospital, and Department of Medicine,2 Université de Montréal, Québec, Canada

Received 23 April 2001/Returned for modification 2 August 2001/Accepted 27 August 2001

Fifty allogeneic stem cell transplant recipients were enrolled in a prospective cytomegalovirus pp65 antigenemia-guided preemptive therapy trial. Among these, 10 of 34 patients who received ganciclovir exhibited sustained and/or recurrent antigenemia despite treatment. Thirteen leukocyte preparations from these 10 subjects were screened for the presence of the most frequent cytomegalovirus UL97 mutations conferring ganciclovir resistance. None of these mutations were detected after mean and median ganciclovir exposures of 31.6 and 28.0 days, respectively.

* Corresponding author. Mailing address: CHUQ-CHUL, Room RC-709, 2705 Blvd. Laurier, Sainte-Foy, Québec, Canada G1V 4G2. Phone: (418) 654-2705. Fax: (418) 654-2715. E-mail: Guy.Boivin{at}crchul.ulaval.ca.

Antimicrobial Agents and Chemotherapy, December 2001, p. 3669-3671, Vol. 45, No. 12
0066-4804/01/$04.00+0   DOI: 10.1128/AAC.45.12.3669-3671.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Gilbert, C., Boivin, G. (2005). Human Cytomegalovirus Resistance to Antiviral Drugs. Antimicrob. Agents Chemother. 49: 873-883 [Full Text]  
  • Meijer, E., Boland, G. J., Verdonck, L. F. (2003). Prevention of Cytomegalovirus Disease in Recipients of Allogeneic Stem Cell Transplants. Clin. Microbiol. Rev. 16: 647-657 [Abstract] [Full Text]  
  • Wolf, D. G., Lurain, N. S., Zuckerman, T., Hoffman, R., Satinger, J., Honigman, A., Saleh, N., Robert, E. S., Rowe, J. M., Kra-Oz, Z. (2003). Emergence of late cytomegalovirus central nervous system disease in hematopoietic stem cell transplant recipients. Blood 101: 463-465 [Abstract] [Full Text]  
  • Eckle, T., Jahn, G., Hamprecht, K. (2003). High Impact of an Expanded Restriction Fragment Length Polymorphism Assay on Detection of Ganciclovir-Resistant UL97 Mutants of Human Cytomegalovirus. Antimicrob. Agents Chemother. 47: 442-443 [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»